Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?

ABSTRACT:

Background

Surgery alone is standard-of-care for stage I gastric adenocarcinoma; however, clinicians can offer preoperative therapy for clinical stage I disease with signet ring cell histology, given its presumed aggressive biology. We aimed to assess the validity of this practice.

Methods

The National Cancer Database (2004-2015) was reviewed for patients with clinical stage I signet ring cell gastric adenocarcinoma who underwent treatment with surgery alone, perioperative chemotherapy, neoadjuvant therapy, or adjuvant therapy. Analysis was stratified by preoperative clinical/pathologic stage. Primary outcome was overall survival (OS).

Results

Of 1018 patients, median age was 60 years (±14); 53% received surgery alone (n = 542), 5% received perioperative chemotherapy

SUBMITTER: Turgeon MK 

PROVIDER: S-EPMC7725995 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature